19:53 , May 2, 2019 |  BC Extra  |  Company News

CStone adds trispecific antibody to pipeline with Numab deal

CStone will provide early stage R&D funding in exchange for exclusive, Asian rights to develop and commercialize preclinical trispecific antibody ND021 from Numab. The immunotherapy, which targets PD-L1, 4-1BB and human serum albumin, would be...
05:16 , Apr 26, 2019 |  BC Week In Review  |  Clinical News

Lilly planning submissions for Taltz in non-radiographic axial spondyloarthritis

Lilly said it plans to submit regulatory applications this year for Taltz ixekizumab to treat non-radiographic axial spondyloarthritis after the drug met the primary and all major secondary endpoints in the Phase III COAST-X trial....
16:18 , Apr 5, 2019 |  BC Week In Review  |  Company News

China’s NMPA approves Novartis’ Cosentyx for psoriasis

Novartis said China's National Medical Products Administration approved Cosentyx secukinumab to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Cosentyx was included on China’s first batch of urgently needed...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
21:17 , Mar 5, 2019 |  BC Extra  |  Company News

Intarcia licenses Numab's autoimmune therapy

Ahead of an NDA resubmission for its Type II diabetes therapy, Intarcia exercised an option to license from Numab exclusive, worldwide rights to autoimmune disorder therapy, ND016. ND016 is a trispecific antibody fragment that blocks...
19:01 , Feb 21, 2019 |  BC Innovations  |  Translation in Brief

Bugging inflammation in lung cancer

An MIT study linking the lung microbiome to inflammation offers new therapeutic strategies for treating lung cancer and a mechanistic rationale for testing cytokine inhibitors in the disease, a tack Novartis AG (NYSE:NVS; SIX:NOVN) has...
16:13 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient samples and mouse studies suggest an antibiotic cocktail or inhibiting IL22RA1 or IL-17A could help treat lung cancer. In tissue samples from patients with lung adenocarcinoma, levels of IL22RA1 were higher...
21:19 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe...
23:31 , Dec 12, 2018 |  BC Extra  |  Clinical News

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe...
20:56 , Nov 29, 2018 |  BC Innovations  |  Translation in Brief

Predicting respiratory response

A University of California San Francisco team has described a gene signature that identifies a subgroup of chronic obstructive pulmonary disease (COPD) patients who could benefit from IL-17A inhibitors if they don’t respond to corticosteroids....